Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
15 mai 2024 07h01 HE
|
Olema Oncology
Across 50 treated patients, palazestrant (OP-1250) in combination with ribociclib was well tolerated with no new safety signals or increased toxicity and no clinically meaningful impact on drug...
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
08 mai 2024 16h02 HE
|
Olema Oncology
Completed enrollment in 60-patient Phase 1b/2 clinical studies of palazestrant in combination with each of ribociclib and palbociclibNew clinical data from palazestrant-ribociclib combination study to...
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
08 mai 2024 07h02 HE
|
Olema Oncology
SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 mai 2024 16h37 HE
|
Olema Oncology
SAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology to Participate in Upcoming Investor Conferences in May
01 mai 2024 07h02 HE
|
Olema Oncology
SAN FRANCISCO, May 01, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
08 avr. 2024 16h30 HE
|
Olema Oncology
SAN FRANCISCO, April 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 avr. 2024 16h29 HE
|
Olema Oncology
SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
11 mars 2024 16h03 HE
|
Olema Oncology
Presented compelling clinical results for palazestrant both as a monotherapy and in combination with CDK4/6 inhibitors, ribociclib and palbociclib, in Q4 2023 Initiated OPERA-01 pivotal Phase 3...
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
06 mars 2024 07h03 HE
|
Olema Oncology
Data published in Molecular Cancer Therapeutics describes the scientific background underlying the design, discovery and optimization of palazestrant (OP-1250)Pre-clinical results demonstrate that...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 mars 2024 16h30 HE
|
Olema Oncology
SAN FRANCISCO, March 04, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...